

Supplementary Table 1. Cox hazards model analysis of variables at the time of the first RTX infusion for serious infection during the first 6 months of follow-up in AAV patients

Variable	Univariable		
	HR	95% CI	p-value
Demographic data			
Age	0.977	0.905, 1.053	0.539
Male	2.538	0.230, 28.016	0.447
MPA versus GPA	1.536	0.139, 16.939	0.726
ANCA positivity			
MPO-ANCA (or P-ANCA) positivity	0.756	0.069, 8.344	0.820
PR3-ANCA (or C-ANCA) positivity	1.146	0.104, 12.641	0.912
Clinical features based on items of BVAS			
General manifestations	1.923	0.174, 21.214	0.593
Cutaneous manifestations	0.041	0.000, 193,268.535	0.684
Mucous and ocular manifestations	4.631	0.418, 51.301	0.212
Otorhinolaryngologic manifestations	2.164	0.196, 23.866	0.529
Pulmonary manifestations	0.238	0.022, 2.631	0.242
Cardiovascular manifestations	4.631	0.418, 51.301	0.212
Gastrointestinal manifestations	0.048	0.000, 4.297E+11	0.841
Renal manifestations	37.499	0.001, 951,717.212	0.484
Nervous systemic manifestations	1.000	0.091, 11.037	1.000
AAV-specific indices			
BVAS	1.130	0.946, 1.350	0.179
FFS	2.110	0.613, 7.267	0.236
Comorbidity			
Chronic kidney disease without RRT	1.260	0.114, 13.897	0.851
Diabetes mellitus	1.624	0.147, 17.914	0.692
Hypertension	0.713	0.065, 7.872	0.783
Dyslipidaemia	0.031	0.000, 1,630.242	0.530
Interstitial lung disease	1.199	0.109, 13.228	0.882
Chronic obstructive pulmonary disease	7.997	0.725, 88.203	0.090
Latent tuberculosis	1.927	0.175, 21.261	0.592
Laboratory results			
White blood cell count	0.829	0.513, 1.341	0.445
Neutrophil count	0.883	0.551, 1.415	0.604
Lymphocyte count	0.290	0.018, 4.689	0.383
Haemoglobin	0.722	0.348, 1.498	0.382
Platelet count	0.997	0.982, 1.013	0.746
Fasting glucose	1.005	0.981, 1.029	0.705
Blood urea nitrogen	1.006	0.956, 1.058	0.824
Creatinine	1.000	0.529, 2.082	0.889
Total protein	0.141	0.010, 1.949	0.144
Serum albumin	0.473	0.038, 5.840	0.559
Acute phase reactants			
ESR (mm/h)	0.916	0.769, 1.091	0.324
CRP (mg/L)	0.896	0.640, 1.253	0.520

The multivariable Cox hazard model using variables with statistical significance in the univariable Cox hazard model was used to obtain hazard ratios (HRs) during follow-up. RTX: rituximab, AAV: ANCA-associated vasculitis, CI: confidence interval, ANCA: antineutrophil cytoplasmic antibody, MPA: microscopic polyangiitis, GPA: granulomatosis with polyangiitis, MPO: myeloperoxidase, P: perinuclear, PR3: proteinase 3, C: cytoplasmic, BVAS: Birmingham vasculitis activity score, FFS: five-factor score, RRT: renal replacement therapy, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein.